Research programme: integrase inhibitors - BioflexisAlternative Names: BFX 1001; BFX 1002; BFX 1003; BFX 1004; BFX 1005; BFX 1006; BFX 1007; BFX 1008
Latest Information Update: 16 Mar 2007
At a glance
- Originator Bioflexis LLC
- Mechanism of Action Chelating agents; HIV integrase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Jan 2006 Preclinical trials in HIV infections in USA (unspecified route)